U.S. market Closed. Opens in 1 day 3 hours 9 minutes

RSLS | ReShape Lifesciences Inc. Stock Fundamentals

(Stock Exchange: NASDAQ)
Analyzing fundamentals for RSLS we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is on medium level and Health is frighteningly weak.

Valuation (12%)

Company Industry
P/E Ratio (TTM) -16.05 48.08
PEG Ratio (TTM) -0.36 -0.81
P/S Ratio (TTM) 0.36 6.09
P/B Ratio (TTM) 47.70 6.08
P/FCF Ratio (TTM) -0.34 42.18
Price to 5YR AVG Earnings Ratio -0.01 59.75
Price to 5YR AVG FCF Ratio -0.19 34.18

Profitability (0%)

Company Industry
ROA (TTM) -141.09% 5.33%
ROE (TTM) -208.37% 27.92%
Net Profit Margin (TTM) -112.11% 7.77%
ROIC 5YR AVG -163.35% 6.77%

Growth (60%)

4QTR AVG 3YR AVG 5YR AVG
EPS 25.43% 43.59% 58.12%
Revenue -3.31% 794.09% 468.42%
Net Income 12.22% -35.64% -1.24%
Cash Flow 30.02% 2.77% -2.32%

Health (26%)

Company Industry
Current Ratio (TTM) 1.90 2.88
Quick Ratio (TTM) 0.89 2.15
D/E Ratio (TTM) 0.07 0.62
Interest Coverage (TTM) 231.55 23.04
Piotroski F-Score 2 6
Altman Z-Score N/A 7.61
LTL to 5YR AVG FCF -0.01 3.48
Shares Outstanding Growth 5YR AVG 424.04% 1.62%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙